In:
Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 20, No. 7 ( 2000-07), p. 1789-1795
Abstract:
Abstract —Low activity of hepatic lipase (HL) has been associated with high levels of triglycerides and high density lipoproteins, but the association of the HL promoter variants with insulin sensitivity has not been investigated. Therefore, in this study, the relationship of the G-250A promoter variant of the HL gene to the rates of insulin-stimulated glucose uptake measured by the hyperinsulinemic euglycemic clamp was investigated in 110 control subjects (82 men and 28 women, aged 50.7±7.6 [mean±SD] years, body mass index 26.1±3.6 kg/m 2 ) and in 105 first-degree relatives (65 men and 40 women, aged 47.8±16.0 years, body mass index 26.9±5.3 kg/m 2 ) of 34 families with familial combined hyperlipidemia (FCHL). The A-250 allele of the HL promoter was associated with low rates of insulin-stimulated whole-body nonoxidative glucose disposal in control subjects (41.1±12.7 μmol · kg −1 · min −1 in subjects with the G-250G genotype, 36.9±13.1 μmol · kg −1 · min −1 in subjects with the G-250A genotype, and 29.9±13.5 μmol · kg −1 · min −1 in subjects with the A-250A genotype; P =0.012 adjusted for age and sex) and with low rates of insulin-stimulated whole-body glucose oxidation in FCHL family members (16.7±4.2 versus 15.0±4.4 versus 14.1±4.4 μmol · kg −1 · min −1 , P =0.024). In addition, the A-250 allele was associated with high levels of fasting insulin ( P =0.047), very low density lipoprotein cholesterol ( P =0.007), and total ( P =0.009) and very low density lipoprotein ( P =0.005) triglycerides in control subjects and with high levels of low density lipoprotein triglycerides ( P =0.001) in FCHL family members (n=340). We conclude that the G-250A promoter variant of the HL gene is associated with dyslipidemia and insulin resistance. Mechanisms via which this polymorphism could affect insulin sensitivity remain to be elucidated.
Type of Medium:
Online Resource
ISSN:
1079-5642
,
1524-4636
DOI:
10.1161/01.ATV.20.7.1789
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2000
detail.hit.zdb_id:
1221433-4
detail.hit.zdb_id:
1494427-3
